[en] Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted therapies" indicates that treatments are directed against specific molecular targets that play a major role in the activation of cell division and in the growth and dissemination of tumors. In particular, targeted therapies were developed against epithelial growth factor receptors and angiogenesis. We can expect specifise therapies against many other targets in the near future. Several drugs have obtained a marketing license. Predictive factors for tumor response and long term outcome should be developed for a better selection of the patient population who will benefit from these treatments. New imaging techniques are under development in order to assess the molecular response to these new approaches.
Disciplines :
Hematology
Author, co-author :
Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Sautois, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Rorive, Andrée ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Language :
French
Title :
Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees
Alternative titles :
[en] Current Therapeutic Progress in Oncology: The Development of Targeted Therapies
Publication date :
2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Dassonville O, Bozec A, Fischel JL, Milano G. - EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors Similarities and differences. Crit Rev Oncol Hematol, 2007, 62, 53-61
O'Brien SG, Guilhot F, Larson RA, et al. - Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003, 348, 994-1004.
Blanke CD, Corless CL. - State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest, 2005, 23, 274-280.
Huang SM, Harari PM. - Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs, 1999, 17, 259-269.
Chung KY, Shia J, Kemeny NE, et al. - Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 2005, 23, 1803-1810.
Cunningham D, Humblet Y, Siena S, et al. - Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351, 337-345.
Van Cutsem E. - Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist, 2006, 11, 1010-1017.
Bonner JA, Harari PM, Giralt J, et al. - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006, 354, 567-578.
Morse L, Calarese P. - EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs, 2006, 22, 152-162.
Perez-Soler R, Delord JP, Halpern A, et al. - HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist, 2005, 10, 345-356.
Valabrega G, Montemurro F, Aglietta M. - Trastuzumab : mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 2007, 1, (Epub ahead of print).
Raff JP, Rajdev L, Malik U, et al. - Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer, 2004, 4, 420-427.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005, 353, 1659-1672.
Romond EH, Perez EA, Bryant J, et al. - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353, 1673-1684.
Smith I, Procter M, Gelber RD, et al. - 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369, 29-36.
Klastersky J. - Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol, 2006, 18, 316-320.
Thatcher N, Chang A, Parikh P, et al. - Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-1537.
Giaccone G, Herbst RS, Manegold C, et al. - Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol, 2004, 22, 777-784.
Herbst RS, Giaccone G, Schiller JH, et al. - Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol, 2004, 22, 785-794.
Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. - Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353, 123-132.
Moy B, Goss PE. - Lapatinib : current status and future directions in breast cancer. Oncologist, 2006, 11, 1047-1057.
Geyer CE, Forster J, Lindquist D, et al. - Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 2006, 355, 2733-2743.
Li WW. - Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol, 2000, 7, 800-811.
Fergelot P, Rioux-Leclercq N, Patard JJ. - Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer. Prog Urol, 2005, 15, 1021-1029.
Bikfalvi A. - Tumor angiogenesis. Bull Cancer, 2003, 90, 449-458.
Hurwitz H, Fehrenbacher L, Novotny W, et al. - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342.
Sandler A, Gray R, Perry MC, et al. - Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355, 2542-2550.
Motzer RJ, Hutson TE, Tomczak P, et al. - Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356, 115-124.
Nelson EC, Evans CP, Lara PN Jr. - Renal cell carcinoma : Current status and emerging therapies. Cancer Treat Rev, 2007, 33, 2-313.
Escudier B, Eisen T, Stadler WM, et al. - Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356, 125-134.
Hahn O, Stadler W. - Sorafenib. Curr Opin Oncol, 2006, 18, 615-621.
Husband JE, Schwartz LH, Spencer J, et al - Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer, 2004, 90, 2256-2260.
